AMD

Astellas

Biotech

Astellas inks $6B Iveric buyout ahead of FDA eye disease ruling

Astellas agreed to pay $5.9 billion to buy Iveric Bio and establish itself as a player in an emerging eye disease niche.

Nick Paul Taylor May 1, 2023 8:13am

layoff

Adverum lays off staff, funnels cash to single eye candidate

Jul 7, 2022 2:27pm

fail

Stealth stumbles again as AMD joins list of clinical trial flops

May 2, 2022 9:05am